13. Safety Profile: Mild Injection Site Reactions

Lepodisiran showed a favorable safety profile in the phase 2 trial. Only 12% of participants reported mild reactions at the injection site, such as redness or tenderness. Importantly, no major safety issues or serious side effects were observed, making the drug well-tolerated overall.